UK COVID-19 passport begins trial

Posted on January 13, 2021 by Jonathan Symcox

iProov

COVID-19 immunity and vaccination passport backed by Innovate UK has entered its live testing phase. 

Developed by British tech firms iProov and Mvine, it enables a person’s test result or vaccination status to be registered and proved without disclosing their identity, and without the need for extensive new infrastructure. 

With additional backing from Innovate UK, which initially funded the development of a successful working prototype, the Mvine-iProov passport will now be tested by Directors of Public Health within the NHS 

Mvine and iProov aim to complete two trials by 31 March 2021. The Mvine-iProov passport can be plugged into the NHS’ existing infrastructure, enabling it to meet the specific needs of local Directors of Public Health and any overarching national requirements.  

They claim this flexibility ensures that areas in different tiers or levels of vaccination rollout can set appropriate policies and enforce them with confidence. 

Frank Joshi, Director at Mvine, said: “Without the need for an extensive new infrastructure, the Directors of Public Health will learn how our innovation is used to promote public health and protect citizen privacy.  

Unlike some other digital solutions for COVID-19, this technology reduces the burden on frontline services and cost-effectively assures a secure and safe way to enable the return to work, return to school and return to the kind of life that people want to lead.” 

Andrew Bud, CEO at iProov, said: “Ensuring consumer trust, security and privacy is essential to the success of projects in this space. iProov enables all three.  

Our Genuine Presence Assurance technology secures the link between the citizen and Mvine’s test status solution in this project, which we think can make an important contribution to forming the national response to the COVID-19 crisis.” 

Events

View All

Insights

View All